Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
By
MIT Sloan affiliate Russell Gong talks about sustainability in healthcare and pitching his company Cabinet Health on 'Shark Tank'.
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
The studies describe new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines.
By
Labor, health, and environmental concerns threaten the might of meat. But alternative foods face major challenges.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
Researchers launched an in-house Data Science and Artificial Intelligence (DSAI) challenge to beat MIT’s machine-learning models for predicting clinical trial outcomes. The results are now available.
MIT Sloan has hundreds of seminars every semester bringing in the world’s leading experts on topics from sustainability to finance. Find out more.
By
Climate tech company BlocPower specializes in residential building electrification, which improves human health and reduces healthcare costs. But no funding exists to link electrification to preventative healthcare efforts. A team of S-Lab students stepped in to help BlocPower make the link.
